Merck & Co., Inc. is 67.4x more valuable than Travere Therapeutics, Inc. by market capitalization ($293.16 B vs $4.35 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TVTX | MRK |
|---|---|---|
| Market cap | $4.35 B | $293.16 B |
| US-listed rank | #1502 | #44 |
| Revenue (latest FY) | $490.73M | $65.01B |
| Net income (latest FY) | -$25.55M | $18.25B |
| Net margin | -5.2% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 1,240 | 996 |
Merck & Co., Inc. is 67.4x more valuable than Travere Therapeutics, Inc. by market capitalization ($293.16 B vs $4.35 B).
In their latest fiscal years, Travere Therapeutics, Inc. reported $490.73M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Travere Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.